pharmaphorum

JANUARY 18, 2023

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. Fast forward to today and, while many large-scale genomics studies still lack the infrastructure and consent policies to enable recontact, this is starting to change. Giving participants something in return. with their priorities.

Genetic Disease 95

Genetic Disease Genetics Research Genome 95

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Generation of strong research dataset cohorts must begin with high-quality clinical samples. Partnerships and Establishing Research Cohorts.

Research 98

Research Biobanking Drugs Genome 98

Delveinsight

DECEMBER 13, 2020

Research and development in Hepatitis. However, there is still a need for further research on HCV and the risk factors that lead to the progression of fibrosis, cirrhosis, and Hepatocellular carcinoma (HCC). Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment durations (usually 8–12 weeks).

Genotype 52

Genotype FDA Approval DNA Drugs 52

XTalks

APRIL 15, 2021

New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.

Development 98

Development Drugs Genome Genomics 98

XTalks

APRIL 29, 2021

However, the variant viral genomes will still persist in the latent reservoir as provirus and can be detected with proviral DNA testing. Importantly, ARV treatment does not affect the proviral DNA genome that persists in latently infected cells. Proviral DNA Genotyping. GenoSure Archive.

DNA 98

DNA Drugs RNA Genotype 98

Drug Discovery World

JULY 15, 2022

The first complete, gapless sequence of a human genome was published 1 April 2022 in a special issue of the journal Science 1. While The Human Genome Project mapped about 92% of the human genome two decades ago, sequencing the last 8% of the genome proved highly challenging.

Genome 52

Genome Genomics DNA Containment 52

XTalks

APRIL 24, 2023

“Rare disease clinical trials are complex due to the additional scientific, medical, operational and regulatory requirements of newly emerging advanced therapies, such as gene therapy,” says Dr. Terence Eagleton, MB BS, Senior Medical Director at the global clinical research organization (CRO) Medpace.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95